Document Detail

Nuclear medicine in the detection and management of pancreatic islet-cell tumours.
MedLine Citation:
PMID:  15763696     Owner:  NLM     Status:  MEDLINE    
Over the last decade somatostatin receptor scintigraphy using various derivatives of long-acting somatostatin analogues has gained its place in the management of pancreatic islet-cell tumours. Scintigraphy is based on the high-affinity binding of such somatostatin analogues to receptors over-expressed by these tumour types. Following the introduction of (111)In-DTPA-D-Phe(1)-octreotide, clinical studies with radiolabelled DOTA-Tyr(3)-octreotide and DOTA-Tyr(3)-octreotate derivatives have shown considerable improvement of imaging results with increased tumour uptake. One of the newer developments, (68)Ga-labelled DOTA-Tyr(3)-octreotide, has shown promising results in patients with pancreatic islet-cell tumours, based on the high-affinity binding to the somatostatin receptor subtype 2 in combination with positron emission tomography (PET) technology. Other peptides--such as ligands for the gastrin/CCK2 receptors or vasoactive intestinal peptide (VIP)--have also been studied for imaging pancreatic cell tumours. Whereas small-sized gastrinoma, somatostatinoma, glucagonoma, carcinoid and VIPoma are frequently detected by somatostatin receptor scintigraphy, insulinoma may escape detection due to reduced receptor expression. Following peptide receptor scintigraphy, a change in patient management is reported in up to 30% of patients. When labelled with (90)Y or (177)Lu, some somatostatin analogues have been applied to patients in advanced stages of the disease. Despite positive response data in 50% of patients, long-term results and survival rates are lacking.
Irene Virgolini; Tatjana Traub-Weidinger; Clemens Decristoforo
Related Documents :
19904746 - Secretin inhibits cholangiocarcinoma growth via dysregulation of the camp-dependent sig...
12065886 - Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulat...
25471566 - Probing α4βδ gabaa receptor heterogeneity: differential regional effects of a functiona...
7616156 - Pancreatic changes in somatostatin content and receptor/effector system after intrapanc...
6144326 - Stimulation of beta 2-adrenergic receptors suppresses sterol synthesis in human mononuc...
9454586 - Transient low-affinity agonist binding to torpedo postsynaptic membranes resolved by us...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Best practice & research. Clinical endocrinology & metabolism     Volume:  19     ISSN:  1521-690X     ISO Abbreviation:  Best Pract. Res. Clin. Endocrinol. Metab.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-03-14     Completed Date:  2005-07-05     Revised Date:  2006-10-30    
Medline Journal Info:
Nlm Unique ID:  101120682     Medline TA:  Best Pract Res Clin Endocrinol Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  213-27     Citation Subset:  IM    
Clinical Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoma, Islet Cell / radionuclide imaging*,  radiotherapy*
Islets of Langerhans / radionuclide imaging*
Nuclear Medicine / methods
Pancreatic Neoplasms / radionuclide imaging*,  radiotherapy*
Radiopharmaceuticals / diagnostic use,  therapeutic use
Somatostatin / analogs & derivatives
Reg. No./Substance:
0/Radiopharmaceuticals; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Imaging and localization of islet-cell tumours of the pancreas on CT and MRI.
Next Document:  Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrin...